ALDESLEUKIN Side Effects

6125500-8 | Hypotension
on Mar 19, 2009 Female patient from UNITED STATES , weighting 34.39 lb, was diagnosed with neuroblastoma (What is neuroblastoma?) and was treated with Aldesleukin (View Usage). Patient experienced the following unwanted or unexpected effects: hypotension. Aldesleukin dosage: 3.15 Mu Daily Iv Drip. During the same period patient was treated with CHIMERIC MAB CH14.18 (17.5 Mg Daily Iv Drip) (View Chimeric Mab -ch14.18- Review and Chimeric Mab -ch14.18- Label ). Patient was hospitalized.

5740068-3 | Acidosis, Acute Respiratory Distress Syndrome, Anoxic Encephalopathy, Arrhythmia Supraventricular, Atrial Fibrillation, Cardiac Arrest, Cardiogenic Shock, Circulatory Collapse, Pulse Absent
Patient was taking Aldesleukin (View Usage). Patient had the following side effects: acidosis, acute respiratory distress syndrome, anoxic encephalopathy, arrhythmia supraventricular, atrial fibrillation (What is atrial fibrillation?), cardiac arrest (What is cardiac arrest?), cardiogenic shock, circulatory collapse, pulse absent on May 08, 2008 from UNITED STATES Additional patient health information: Male patient , 70 years of age, was diagnosed with metastatic renal cell carcinoma and. Aldesleukin dosage: . Patient was hospitalized.

5719414-2 | Eye Pruritus, Iridocyclitis, Iritis, Vision Blurred
Adverse event was reported on Apr 17, 2008 by a Female patient taking Aldesleukin (View Usage) (Dosage: ) was diagnosed with metastatic renal cell carcinoma and. Location: UNITED STATES , 63 years of age, weighting 151.5 lb, After Aldesleukin was administered, patient had the following side effects: eye pruritus, iridocyclitis, iritis, vision blurred. During the same period patient was treated with ATIVAN (View Ativan Review and Ativan Label ), XANAX (View Xanax Review and Xanax Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ).

5697473-3 | Aphasia, Autoimmune Thrombocytopenia, Cerebral Infarction, Coma, Confusional State, Dyspnoea, Escherichia Sepsis, Haemorrhage Intracranial, Headache
on Apr 01, 2008 Male patient from NETHERLANDS , 58 years of age, weighting 154.3 lb, was diagnosed with acute myeloid leukaemia and was treated with Aldesleukin (View Usage). Patient experienced the following unwanted or unexpected effects: aphasia (What is aphasia?), autoimmune thrombocytopenia, cerebral infarction, coma, confusional state, dyspnoea, escherichia sepsis, haemorrhage intracranial, headache (What is headache?). Aldesleukin dosage: 8. Patient was hospitalized.


5688664-6 | Clostridium Difficile Colitis, Gastrointestinal Disorder, Ileus, Nausea, Oral Intake Reduced, Small Intestinal Obstruction
on Mar 19, 2008 Female patient from UNITED STATES , 64 years of age, weighting 171.7 lb, was diagnosed with metastatic renal cell carcinoma and was treated with Aldesleukin (View Usage). Patient had the following side effects: clostridium difficile colitis, gastrointestinal disorder, ileus, nausea (What is nausea?), oral intake reduced, small intestinal obstruction. Aldesleukin dosage: 50 Iu Every 8 Hours. Patient was hospitalized.

5677294-8 | Clostridium Difficile Colitis, Nausea, Oral Intake Reduced, Small Intestinal Obstruction
Patient was taking Aldesleukin (View Usage). After Aldesleukin was administered, patient had the following side effects: clostridium difficile colitis, nausea (What is nausea?), oral intake reduced, small intestinal obstruction on Mar 20, 2008 from UNITED STATES Additional patient health information: Female patient , 64 years of age, weighting 171.7 lb, was diagnosed with metastatic renal cell carcinoma and. Aldesleukin dosage: 50,000,000 Iu Every 8 Hours Iv. Patient was hospitalized.

5677293-6 | Anxiety, Depression, Fatigue, Insomnia, Suicidal Ideation
Adverse event was reported on Mar 20, 2008 by a Female patient taking Aldesleukin (View Usage) (Dosage: 50,000,000 Iu Every 8 Hours Iv) was diagnosed with metastatic renal cell carcinoma, depression (What is depression?) and. Location: UNITED STATES , 64 years of age, weighting 171.7 lb, Patient experienced the following unwanted or unexpected effects: anxiety (What is anxiety?), depression (What is depression?), fatigue, insomnia, suicidal ideation. During the same period patient was treated with PAROXETINE HCL (10 Mg Every Day Po) (View Paroxetine Hcl Review and Paroxetine Hcl Label ). Patient was hospitalized.

5575998-9 | Aphasia, Cognitive Disorder, Dysphemia, Speech Disorder
on Dec 20, 2007 Male patient from UNITED STATES , 49 years of age, weighting 207.0 lb, was diagnosed with metastatic renal cell carcinoma and was treated with Aldesleukin (View Usage). Patient had the following side effects: aphasia (What is aphasia?), cognitive disorder, dysphemia, speech disorder. Aldesleukin dosage: 0.6mu/kg/dose Q8 Hours. During the same period patient was treated with BEVACIZUMAB (10mg/kg Q2wks) (View Bevacizumab Review and Bevacizumab Label ), MEPERIDINE (View Meperidine Review and Meperidine Label ), PEPCID (View Pepcid Review and Pepcid Label ), INDOCIN (View Indocin Review and Indocin Label ), DILAUDID (View Dilaudid Review and Dilaudid Label ), TYLENOL (View Tylenol Review and Tylenol Label ), LORTAB (View Lortab Review and Lortab Label ), AMBIEN (View Ambien Review and Ambien Label ).

5525799-2 | Aphasia, Cerebral Infarction, Coma, Confusional State, Dyspnoea, Escherichia Sepsis, Haemorrhage Intracranial, Headache, Idiopathic Thrombocytopenic Purpura
on Oct 29, 2007 Male patient from NETHERLANDS , 58 years of age, weighting 154.3 lb, was diagnosed with acute myeloid leukaemia and was treated with Aldesleukin (View Usage). After Aldesleukin was administered, patient had the following side effects: aphasia (What is aphasia?), cerebral infarction, coma, confusional state, dyspnoea, escherichia sepsis, haemorrhage intracranial, headache (What is headache?), idiopathic thrombocytopenic purpura. Aldesleukin dosage: 8. Patient was hospitalized.

5520249-4 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Asthenia, Blood Alkaline Phosphatase Abnormal, Cardio-respiratory Arrest, Diarrhoea, Hepatic Failure, Hyperbilirubinaemia, Malignant Neoplasm Progression
Patient was taking Aldesleukin (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, asthenia, blood alkaline phosphatase abnormal, cardio-respiratory arrest, diarrhoea, hepatic failure, hyperbilirubinaemia, malignant neoplasm progression on Oct 29, 2007 from UNITED STATES Additional patient health information: Female patient , 69 years of age, weighting 131.0 lb, was diagnosed with metastatic renal cell carcinoma and. Aldesleukin dosage: . Patient was hospitalized.

5518136-0 | Blood Culture Positive, Central Line Infection
Adverse event was reported on Nov 13, 2007 by a Male patient taking Aldesleukin (View Usage) (Dosage: 77.76 Million Units Every 8 Hours Iv) was diagnosed with metastatic malignant melanoma and. Location: UNITED STATES , 55 years of age, weighting 224.9 lb, Patient had the following side effects: blood culture positive, central line infection. During the same period patient was treated with ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), NAFCILLIN SODIUM (View Nafcillin Sodium Review and Nafcillin Sodium Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), METOPROLOL (View Metoprolol Review and Metoprolol Label ), NAPROXEN (View Naproxen Review and Naproxen Label ), POTASSIUM CHLORIDE (View Potassium Chloride Review and Potassium Chloride Label ), PIPERACILLIN AND TAZOBACTAM (View Piperacillin And Tazobactam Review and Piperacillin And Tazobactam Label ). Patient was hospitalized.

5474088-3 | Chills, Ejaculation Disorder, Epididymitis, Hydrocele, Orchitis, Sepsis, Testicular Pain, Testicular Swelling, Vomiting
on Sep 20, 2007 Male patient from , 32 years of age, was diagnosed with hiv infection (What is hiv infection?) and was treated with Aldesleukin (View Usage). After Aldesleukin was administered, patient had the following side effects: chills, ejaculation disorder, epididymitis, hydrocele, orchitis, sepsis (What is sepsis?), testicular pain, testicular swelling, vomiting. Aldesleukin dosage: 9 Miu, Every 6-8 Months. During the same period patient was treated with LAMIVUDINE (View Lamivudine Review and Lamivudine Label ), STAVUDINE (View Stavudine Review and Stavudine Label ), DDI (View Ddi Review and Ddi Label ). Patient was hospitalized.

5453658-2 | Aphasia, Cerebral Infarction, Coma, Confusional State, Dyspnoea, Escherichia Sepsis, Haemorrhage Intracranial, Headache, Idiopathic Thrombocytopenic Purpura
on Sep 13, 2007 Male patient from NETHERLANDS , 58 years of age, weighting 154.3 lb, was diagnosed with acute myeloid leukaemia and was treated with Aldesleukin (View Usage). Patient experienced the following unwanted or unexpected effects: aphasia (What is aphasia?), cerebral infarction, coma, confusional state, dyspnoea, escherichia sepsis, haemorrhage intracranial, headache (What is headache?), idiopathic thrombocytopenic purpura. Aldesleukin dosage: 8. Patient was hospitalized.

5453641-7 | Chills, Ejaculation Disorder, Epididymitis, Hydrocele, Orchitis, Sepsis, Testicular Pain, Testicular Swelling, Vomiting
Patient was taking Aldesleukin (View Usage). Patient had the following side effects: chills, ejaculation disorder, epididymitis, hydrocele, orchitis, sepsis (What is sepsis?), testicular pain, testicular swelling, vomiting on Sep 04, 2007 from Additional patient health information: Male patient , 32 years of age, was diagnosed with hiv infection (What is hiv infection?) and. Aldesleukin dosage: 9 Miu, Every 6-8 Months. During the same period patient was treated with LAMIVUDINE (View Lamivudine Review and Lamivudine Label ), STAVUDINE (View Stavudine Review and Stavudine Label ), DDI (View Ddi Review and Ddi Label ). Patient was hospitalized.

5452198-4 | Chills, Ejaculation Disorder, Epididymitis, Orchitis, Sepsis, Testicular Pain, Testicular Swelling, Vomiting
Adverse event was reported on Sep 04, 2007 by a Male patient taking Aldesleukin (View Usage) (Dosage: 9 Miu, Every 6-8 Months) was diagnosed with hiv infection (What is hiv infection?) and. Location: , 32 years of age, After Aldesleukin was administered, patient had the following side effects: chills, ejaculation disorder, epididymitis, orchitis, sepsis (What is sepsis?), testicular pain, testicular swelling, vomiting. During the same period patient was treated with LAMIVUDINE (View Lamivudine Review and Lamivudine Label ), STAVUDINE (View Stavudine Review and Stavudine Label ), DDI (View Ddi Review and Ddi Label ). Patient was hospitalized.

5444607-1 | Aphasia, Cerebral Infarction, Confusional State, Dyspnoea, Escherichia Sepsis, Haemorrhage Intracranial, Headache, Idiopathic Thrombocytopenic Purpura, Platelet Count Decreased
on Aug 10, 2007 Male patient from NETHERLANDS , 58 years of age, weighting 154.3 lb, was diagnosed with acute myeloid leukaemia and was treated with Aldesleukin (View Usage). Patient experienced the following unwanted or unexpected effects: aphasia (What is aphasia?), cerebral infarction, confusional state, dyspnoea, escherichia sepsis, haemorrhage intracranial, headache (What is headache?), idiopathic thrombocytopenic purpura, platelet count decreased. Aldesleukin dosage: 8. Patient was hospitalized.

5232630-1 | Haemoglobin Decreased, Red Blood Cell Sedimentation Rate Increased, Skin Hypertrophy, Systemic Sclerosis, White Blood Cell Count Increased
on Jan 29, 2007 Female patient from FRANCE , 49 years of age, was diagnosed with renal cell carcinoma recurrent and was treated with Aldesleukin (View Usage). Patient had the following side effects: haemoglobin decreased, red blood cell sedimentation rate increased, skin hypertrophy, systemic sclerosis, white blood cell count increased. Aldesleukin dosage: 11 X 10e6 U M-2 Qw3. Patient was hospitalized.

5157213-3 | Haemoglobin Decreased, Red Blood Cell Sedimentation Rate Increased, Skin Hypertrophy, Systemic Sclerosis, White Blood Cell Count Increased
Patient was taking Aldesleukin (View Usage). After Aldesleukin was administered, patient had the following side effects: haemoglobin decreased, red blood cell sedimentation rate increased, skin hypertrophy, systemic sclerosis, white blood cell count increased on Nov 14, 2006 from FRANCE Additional patient health information: Female patient , 49 years of age, was diagnosed with renal cell carcinoma recurrent and. Aldesleukin dosage: 11 X 10e6 U M-2 Qw3. Patient was hospitalized.

5015301-6 | Atrial Fibrillation, Ejection Fraction Decreased, Hypotension, Myocardial Infarction
Adverse event was reported on May 30, 2006 by a Female patient taking Aldesleukin (View Usage) (Dosage: Iv) was diagnosed with metastatic malignant melanoma and. Location: UNITED STATES , 67 years of age, Patient experienced the following unwanted or unexpected effects: atrial fibrillation (What is atrial fibrillation?), ejection fraction decreased, hypotension, myocardial infarction.

5010775-9 | Confusional State, Disease Progression, Dyspnoea, Pleural Effusion
on May 24, 2006 Male patient from UNITED STATES , 63 years of age, weighting 205.0 lb, was treated with Aldesleukin (View Usage). Patient had the following side effects: confusional state, disease progression, dyspnoea, pleural effusion. Aldesleukin dosage: 11 M14 Sq D1-5 X6 Wks. During the same period patient was treated with CYTOMEL (View Cytomel Review and Cytomel Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), PROLEUKIN (View Proleukin Review and Proleukin Label ), AVASTIN (View Avastin Review and Avastin Label ), LEXAPRO (View Lexapro Review and Lexapro Label ), DILAUDID (View Dilaudid Review and Dilaudid Label ), COMPAZINE (View Compazine Review and Compazine Label ). Patient was hospitalized.

4673987-X | Cardiac Disorder, Coronary Artery Stenosis, Ejection Fraction Decreased
on May 09, 2005 Male patient from , 69 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Aldesleukin (View Usage). After Aldesleukin was administered, patient had the following side effects: cardiac disorder, coronary artery stenosis, ejection fraction decreased. Aldesleukin dosage: 14 Miu Tiw Subcutaneous. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), SOTALOL HCL (View Sotalol Hcl Review and Sotalol Hcl Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), ACETYLSALICYLIC LYSINE (View Acetylsalicylic Lysine Review and Acetylsalicylic Lysine Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), RAMIPRIL (View Ramipril Review and Ramipril Label ), SERENOA REPENS (View Serenoa Repens Review and Serenoa Repens Label ), DIHYDROERGOCRYPTINE MEZILATE/CAFEINE (View Dihydroergocryptine Mezilate/cafeine Review and Dihydroergocryptine Mezilate/cafeine Label ). Patient was hospitalized.